



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Ulrich Schubert et al. Examiner: Mary Mosher  
Serial No.: 09/913,927 Group Art Unit: 1648  
Filed: January 14, 2002 Docket: G&C 151.2-US-WO  
Title: SYNTHETIC PEPTIDE OF REGULATORY VIRUS PROTEIN R (VPR) OF  
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) AND THE  
UTILIZATION THEREOF

**CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on July 5, 2002.

By:   
Name: Karen S. Canady

**STATEMENT REGARDING SEQUENCE LISTING**  
**UNDER 37 C.F.R. §§ 1.821-1.825**

Commissioner for Patents  
Washington, D.C. 20231

**COPY OF PAPERS  
ORIGINALLY FILED**

Dear Sir:

In accordance with 37 CFR § 1.821(f), Applicants hereby state that the paper and computer readable copies of the Sequence Listing submitted herewith in connection with the above-identified patent application are the same. The Sequence Listing submitted herewith does not include new matter or matter which goes beyond the application as originally filed.

In accordance with 37 CFR § 1.825(a), Applicants hereby state that the amendments included in the substitute sheets of the Sequence Listing are hereby supported by the application as originally filed, as follows:

SEQ ID NO: 10 is supported by the specification at page 8, line 17-19; and

SEQ ID NO: 11 is supported by the specification at page 8, line 21-23.

Applicants hereby state further that the substitute sheets of the Sequence Listing submitted herewith do not introduce new matter.


Respectfully submitted,

GATES & COOPER LLP  
Attorneys for Applicant(s)

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, California 90045  
(310) 641-8797

Date: July 5, 2002

KSC/sjm  
G&C 151.2-US-WO

By:   
Name: Karen S. Canady  
Reg. No.: 39,927



Application No.: 09/913,927

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

**COPY OF PAPERS  
ORIGINALLY FILED**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**